{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ebselen", "query": { "intervention": "Ebselen" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 13, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ebselen&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-06T01:15:35.190Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01444846", "title": "Otoprotection With SPI-1005 for Prevention of Temporary Auditory Threshold Shift", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Temporary Auditory Threshold Shift" ], "interventions": [ { "name": "SPI-1005 Low dose", "type": "DRUG" }, { "name": "SPI-1005 Middle dose", "type": "DRUG" }, { "name": "SPI-1005 High dose", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sound Pharmaceuticals, Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "31 Years", "sex": "ALL", "summary": "18 Years to 31 Years" }, "enrollment_count": 83, "start_date": "2011-09", "completion_date": "2014-03", "has_results": true, "last_update_posted_date": "2026-06-03", "last_synced_at": "2026-09-06T01:15:35.190Z", "location_count": 1, "location_summary": "Gainesville, Florida", "locations": [ { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01444846" }, { "nct_id": "NCT02819856", "title": "SPI-1005 for Prevention and Treatment of Tobramycin Induced Ototoxicity", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ototoxicity" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "SPI-1005 Ebselen 200mg Capsule x1", "type": "DRUG" }, { "name": "SPI-1005 Ebselen 200mg Capsule x2", "type": "DRUG" }, { "name": "SPI-1005 Ebselen 200mg Capsule x3", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sound Pharmaceuticals, Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2017-07-21", "completion_date": "2023-04-07", "has_results": true, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-09-06T01:15:35.190Z", "location_count": 1, "location_summary": "Charleston, South Carolina", "locations": [ { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02819856" }, { "nct_id": "NCT00762671", "title": "Signaling Mechanisms and Vascular Function in Patients With Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Type 1 Diabetes Mellitus", "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Ebselen", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 60, "start_date": "1999-05", "completion_date": "2007-10", "has_results": false, "last_update_posted_date": "2008-09-30", "last_synced_at": "2026-09-06T01:15:35.190Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00762671" }, { "nct_id": "NCT04483973", "title": "SPI-1005 Treatment in Severe COVID-19 Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Covid19", "Coronavirus", "Coronavirus Infection", "Corona Virus Infection" ], "interventions": [ { "name": "Ebselen", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sound Pharmaceuticals, Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2021-08-27", "completion_date": "2023-06-06", "has_results": true, "last_update_posted_date": "2026-06-29", "last_synced_at": "2026-09-06T01:15:35.190Z", "location_count": 7, "location_summary": "New Haven, Connecticut • Boise, Idaho • Kansas City, Kansas + 4 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Boise", "state": "Idaho" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04483973" }, { "nct_id": "NCT02779192", "title": "A Phase 2b Study of SPI-1005 to Prevent Acute Noise Induced Hearing Loss", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Noise Induced Hearing Loss" ], "interventions": [ { "name": "SPI-1005 200mg", "type": "DRUG" }, { "name": "SPI-1005 400mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sound Pharmaceuticals, Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 0, "start_date": "2026-06", "completion_date": "2026-06", "has_results": false, "last_update_posted_date": "2026-06-03", "last_synced_at": "2026-09-06T01:15:35.190Z", "location_count": 5, "location_summary": "Miami, Florida • Kansas City, Kansas • Charleston, South Carolina + 2 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Charleston", "state": "South Carolina" }, { "city": "Dallas", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02779192" }, { "nct_id": "NCT06859788", "title": "SPI-1005 for the Treatment of Meniere's Disease (Open Label)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Meniere's Disease", "Ménière's Disease" ], "interventions": [ { "name": "Ebselen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sound Pharmaceuticals, Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 200, "start_date": "2025-10-29", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-07-13", "last_synced_at": "2026-09-06T01:15:35.190Z", "location_count": 9, "location_summary": "Los Angeles, California • Boynton Beach, Florida • Delray Beach, Florida + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Boynton Beach", "state": "Florida" }, { "city": "Delray Beach", "state": "Florida" }, { "city": "New Hyde Park", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06859788" }, { "nct_id": "NCT06340633", "title": "SPI-1005 in Adults Receiving Cochlear Implant", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hearing Loss", "Cochlear Trauma" ], "interventions": [ { "name": "Ebselen", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sound Pharmaceuticals, Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2026-12", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-06-26", "last_synced_at": "2026-09-06T01:15:35.190Z", "location_count": 6, "location_summary": "Iowa City, Iowa • Columbus, Ohio • Philadelphia, Pennsylvania + 3 more", "locations": [ { "city": "Iowa City", "state": "Iowa" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Charleston", "state": "South Carolina" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06340633" }, { "nct_id": "NCT02603081", "title": "Study to Evaluate SPI-1005 in Adults With Meniere's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Meniere's Disease" ], "interventions": [ { "name": "SPI-1005", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sound Pharmaceuticals, Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "19 Years to 70 Years" }, "enrollment_count": 40, "start_date": "2015-12", "completion_date": "2017-08", "has_results": true, "last_update_posted_date": "2026-06-29", "last_synced_at": "2026-09-06T01:15:35.190Z", "location_count": 5, "location_summary": "Los Angeles, California • New York, New York • Charleston, South Carolina + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "Charleston", "state": "South Carolina" }, { "city": "Seattle", "state": "Washington" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02603081" }, { "nct_id": "NCT04677972", "title": "SPI-1005 for the Treatment of Meniere's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Meniere Disease", "Ménière" ], "interventions": [ { "name": "Ebselen", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sound Pharmaceuticals, Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 220, "start_date": "2022-08-02", "completion_date": "2024-07-25", "has_results": true, "last_update_posted_date": "2026-07-23", "last_synced_at": "2026-09-06T01:15:35.190Z", "location_count": 12, "location_summary": "Little Rock, Arkansas • Los Angeles, California • Roseville, California + 8 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Roseville", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04677972" }, { "nct_id": "NCT01451853", "title": "SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer", "Head and Neck Cancer", "Hearing Loss", "Ototoxicity", "Tinnitus", "Neuropathy" ], "interventions": [ { "name": "SPI-1005 Low Dose", "type": "DRUG" }, { "name": "SPI-1005 Middle Dose", "type": "DRUG" }, { "name": "SPI-1005 High Dose", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sound Pharmaceuticals, Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "19 Years to 80 Years" }, "enrollment_count": 0, "start_date": "2026-06", "completion_date": "2026-06", "has_results": false, "last_update_posted_date": "2026-06-03", "last_synced_at": "2026-09-06T01:15:35.190Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01451853" } ] }